Welcome to our dedicated page for Amphastar Pharma news (Ticker: AMPH), a resource for investors and traders seeking the latest updates and insights on Amphastar Pharma stock.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a biopharmaceutical company focused on technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin API products. The AMPH news feed on Stock Titan brings together the company’s press releases and market-moving updates so readers can follow how its product portfolio, licensing deals, and financial performance evolve over time.
News about Amphastar often centers on regulatory milestones and pipeline progress. The company has reported U.S. Food and Drug Administration approval of its ANDA for Iron Sucrose Injection, USP, a generic iron sucrose injection indicated for iron deficiency anemia in chronic kidney disease. It also issues updates on its ANDAs, biosimilar insulin candidate, and proprietary peptide and protein products, including licensed peptide assets targeting oncology and ophthalmology.
Another recurring theme in AMPH news is strategic licensing and research agreements. Amphastar has announced exclusive license agreements with Nanjing Anji Biotechnology Co., Ltd. and Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for proprietary peptide products and for AMP-110, a fully synthetic ACTH analog in early-phase human clinical development. The company also discloses contract research agreements for recombinant peptide research cell banks supporting its pipeline.
Investors can also track quarterly earnings releases, non-GAAP financial metrics, and share repurchase authorizations, as well as announcements about expanded manufacturing capacity and distribution partnerships, such as the exclusive distribution of BAQSIMI® in parts of the Greater China region. By following AMPH news, readers gain insight into Amphastar’s mix of complex generics, proprietary medicines, manufacturing footprint, and related-party agreements that shape its long-term business profile.
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q2 2025 financial results with net revenues of $174.4 million and GAAP net income of $31.0 million ($0.64 per share). The company's adjusted non-GAAP net income was $40.9 million ($0.85 per share).
BAQSIMI® emerged as a key revenue driver with a 51% increase to $46.7 million, while the company faced challenges with decreased sales in epinephrine (-42%) and glucagon (-25%). The company announced a major strategic initiative to quadruple manufacturing capacity at its Rancho Cucamonga headquarters. Additionally, the Board authorized a $50 million increase to the share buyback program.
The company's pipeline includes 4 ANDAs and one biosimilar insulin candidate filed with FDA, targeting products with a combined market size exceeding $3 billion, plus three biosimilar products targeting a $6 billion market.
Amphastar Pharmaceuticals (NASDAQ:AMPH) has scheduled its second quarter 2025 earnings release and conference call for August 7, 2025. The financial results will be released after market close, followed by a conference call at 2:00 p.m. Pacific Time.
Amphastar is a bio-pharmaceutical company specializing in developing, manufacturing, and marketing technically challenging generic and proprietary injectable, inhalation, and intranasal products. The company also produces insulin API products, with most of its finished products being used in hospital or urgent care clinical settings.
Amphastar Pharmaceuticals (NASDAQ:AMPH) has announced a significant expansion of its U.S. manufacturing operations at its Rancho Cucamonga, California headquarters. The company plans to quadruple its production capacity over the next 3-5 years, marking its largest domestic infrastructure investment to date.
The expansion includes a new state-of-the-art production plant, enhanced automation, and advanced technologies integration to support critical medication production and pipeline candidates. The initiative will create new jobs across R&D, engineering, manufacturing, and quality operations. Notably, all of Amphastar's finished pharmaceutical products are manufactured in the U.S., reinforcing their commitment to domestic production and supply chain resilience.
Amphastar Pharmaceuticals (NASDAQ:AMPH) announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's CFO Bill Peters and EVP of Corporate Administration Jacob Liawatidewi will engage in an analyst-moderated fireside chat on June 5th, 2025, at 2:00 pm ET. Investors can access the presentation through Amphastar's website at ir.amphastar.com, with the webcast remaining available for 30 days after the event.
Amphastar Pharmaceuticals (NASDAQ:AMPH) announced that its CFO Bill Peters and SVP of Corp. Communication Dan Dischner will participate in a fireside chat at the 2025 Bank of America Health Care Conference. The presentation is scheduled for Wednesday, May 14th, 2025, at 1:40 pm PT. Investors can access the webcast through Amphastar's website at http://ir.amphastar.com, and the recording will remain available for 30 days after the presentation.
Amphastar Pharmaceuticals has scheduled its Q1 2025 earnings release and conference call for May 7th, 2025. The company will disclose financial results after market close, followed by a conference call at 2:00 p.m. Pacific Time.
Amphastar, a bio-pharmaceutical company, specializes in developing and manufacturing complex injectable, inhalation, and intranasal products. Their product portfolio includes technically challenging generic and proprietary medications, primarily used in hospitals and urgent care settings. The company also produces insulin API products and distributes through group purchasing organizations and drug wholesalers.
Investors can join the conference call via toll-free number 877-407-0989 or international number 201-389-0921. A webcast will be available on the company's website, with a replay accessible within 24 hours after the live call.
Amphastar Pharmaceuticals (NASDAQ:AMPH) has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company will be represented by CFO Bill Peters and SVP of Corp. Communication Dan Dischner in an analyst-moderated fireside chat scheduled for Wednesday, April 9th, 2025, at 1:30 pm ET.
The presentation will be accessible through Amphastar's investor relations website at http://ir.amphastar.com, with the webcast remaining available for 30 days following the event.
Amphastar Pharmaceuticals (NASDAQ:AMPH) subsidiary International Medication Systems (IMS) has received the FDA's Drug Shortage Assistance Award for addressing the shortage of epinephrine injection 0.1 mg/mL syringes. The recognition highlights IMS's efforts in submitting and obtaining approval of a new drug application for epinephrine injection.
The company's pipeline includes 4 ANDAs targeting products with >$2 billion market size, 4 biosimilar products targeting >$7 billion market size, and 2 generic products targeting >$1.3 billion market size, based on IQVIA data for 2024. Amphastar is developing multiple proprietary products with injectable and intranasal dosage forms.
Amphastar Pharmaceuticals (NASDAQ:AMPH) has announced its participation in the upcoming Barclays 27th Annual Global Healthcare Conference. The company will be represented by Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, who are scheduled to present on Wednesday, March 12th, 2025, at 10:30 am ET.
Interested parties can access the presentation through Amphastar's investor relations website at http://ir.amphastar.com. The webcast recording will remain accessible for 30 days following the presentation.
FAQ
What is the current stock price of Amphastar Pharma (AMPH)?
What is the market cap of Amphastar Pharma (AMPH)?
